A Phase II Study of Efficacy and Tolerance of Azacitidine (AZA) In MDS-associated Steroid Dependent/Refractory Systemic Auto-immune and Inflammatory Disorders (SAID)
Latest Information Update: 11 Jul 2023
At a glance
- Drugs Azacitidine (Primary)
- Indications Acute myeloid leukaemia; Autoimmune disorders; Chronic myelomonocytic leukaemia; Inflammation; Myelodysplastic syndromes
- Focus Therapeutic Use
- 03 Jun 2023 Results presented at the 24th Annual Congress of the European League Against Rheumatism
- 11 Oct 2021 Planned End Date changed from 1 Feb 2023 to 1 Oct 2022.
- 18 Jun 2020 Status changed from recruiting to active, no longer recruiting.